BIO-RAD LABORATORIES, INC. (BIO) FY2026 Q2 P&L / Income Statement

BIO-RAD LABORATORIES, INC. (BIO) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue and costs use their disclosed categories.

Net sales

651,000,000 US dollars

Cost of goods sold

305,200,000 US dollars

Gross profit

345,800,000 US dollars

Operating expenses (calculated)

273,200,000 US dollars

Segment profit (loss)

72,600,000 US dollars

Other income (expense), net (calculated)

469,500,000 US dollars

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

542,100,000 US dollars

(Provision) benefit for income taxes

170,700,000 US dollars

Net income attributable to Bio-Rad

371,400,000 US dollars

Life Science revenue

252,000,000 US dollars

Clinical Diagnostics revenue

399,000,000 US dollars

Life Science cost of revenue

108,500,000 US dollars

Clinical Diagnostics cost of revenue

196,700,000 US dollars

Selling, general and administrative expense

212,000,000 US dollars

Research and Development Expense

61,200,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.